Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

61.46
-0.9400-1.51%
Post-market: 61.680.2214+0.36%19:59 EDT
Volume:10.77M
Turnover:663.45M
Market Cap:125.12B
PE:13.53
High:62.61
Open:62.20
Low:61.25
Close:62.40
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.76
T/O Rate:0.53%
Dividend:2.51
Dividend Rate:4.08%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.61
PE(LYR):17.76

Loading ...

Bladder Cancer Trial Completion Puts Opdivo in Focus for BMY and Ono Investors

TIPRANKS
·
Sep 11

Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says

MT Newswires Live
·
Sep 11

Bristol-Myers Squibb is Maintained at Hold by HSBC

Dow Jones
·
Sep 10

Bloomsbury Executives Adjust Holdings After 2023 Share Plan Vesting

TIPRANKS
·
Sep 10

HSBC Adjusts Price Target on Bristol-Myers Squibb to $65 From $60, Keeps Hold Rating

MT Newswires Live
·
Sep 10

Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)

TIPRANKS
·
Sep 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY), Stryker (SYK) and InnovAge Holding (INNV)

TIPRANKS
·
Sep 09

CD&R Appoints Novartis Chair Giovanni Caforio Operating Advisor to Funds

Reuters
·
Sep 09

Bristol Myers Squibb Co. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.25% on Sep 8: Facts Behind the Movement

TradingKey
·
Sep 09

Movement Alert|Bristol-Myers Squibb Falls 3.05% in Regular Trading, CAR-T Safety Concerns Across Sector Offset Positive Clinical Data

Market Focus
·
Sep 08

Bristol Myers Squibb's Phase 2 Study of Arlocabtagene Autoleucel Meets Key Endpoints

MT Newswires Live
·
Sep 08

Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial

TIPRANKS
·
Sep 08

Bristol Myers Squibb's Therapy Meets Mid-Stage Trial Goal

Reuters
·
Sep 08

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 Quintessential Trial of the Potential First-in-Class Gprc5d-Directed Car T Cell Therapy, Arlocabtagene Autoleucel ...

THOMSON REUTERS
·
Sep 08

Bristol-Myers Squibb Company - Phase 2 Trial Met Primary Endpoint of Overall Response Rate and Complete Response Rate

THOMSON REUTERS
·
Sep 08

Bristol-Myers Squibb Company - Arlo-Cel Safety Profile Consistent with Other Car T Cell Therapies

THOMSON REUTERS
·
Sep 08

Jeito Capital Promotes Pascal Touchon to Partner

Reuters
·
Sep 08

Berenberg Bank Sticks to Its Buy Rating for Bloomsbury Publishing (BMY)

TIPRANKS
·
Sep 08

Bristol Myers Squibb Co. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05